FluoroPharma Medical, Inc. (FPMI) Offers Major Market Advantages
For developing businesses, one of the keys to potential growth is to present products that have unique benefits not found elsewhere, providing a decided advantage in the marketplace. In the rapidly...
View ArticleFluoroPharma Medical, Inc. (FPMI) Targets #1 Most Wanted
In 1950, the FBI formally announced their Ten Most Wanted list to the world, in an attempt to promote the identification and capture of the most notorious fugitives. If there were a ten most wanted...
View ArticleLifeTech Capital Provides Coverage Update on FluoroPharma Medical, Inc. (FPMI)
Earlier this week, LifeTech Capital issued an update on its FluoroPharma Medical coverage. The latest report reiterates the stock as a “Strong Speculative Buy” and sets a $2.50 price target. The entire...
View ArticleFluoroPharma Medical, Inc. (FPMI) is “One to Watch”
FluoroPharma Medical, Inc. is a biopharmaceutical company focused on discovering and developing patented Positron Emission Tomography (PET) imaging products to improve patient management by evaluating...
View ArticleFluoroPharma Medical (FPMI) Supports Growing Movement for Personalized Medicine
One of the buzzword terms in modern medicine today is “personalized medicine”. Instead of simply matching a drug or treatment to an over-arching disease based on a one-size-fits-all philosophy, as has...
View ArticleThe Case for FluoroPharma Medical, Inc. (FPMI)
FluoroPharma Medical is a New Jersey based developer of advanced imaging pharmaceuticals for use with positron emission tomography (PET). The company provides unique radiopharmaceutical imaging agents,...
View ArticleFluoroPharma Medical, Inc. (FPMI) Targets Piece of $7 Billion Market Growing...
FluoroPharma, a developer of imaging drugs that underpin important diagnostic capabilities of positron emission tomography (PET), targets a fast-growing market. This market is currently over $7 billion...
View ArticleFluoroPharma Medical, Inc. (FPMI) Targets Two of the Biggest Medical Markets
FluoroPharma is developing breakthrough molecular imaging agents for use with positron emission tomography (PET) designed to fulfill critical unmet medical needs. These new agents give clinicians...
View ArticleFluoroPharma Medical (FPMI) Guided By Industry Leaders
FluoroPharma develops and commercializes proprietary medical diagnostic imaging products for use with positron emission tomography (PET). The company’s current focus is on the detection and assessment...
View ArticleFluoroPharma Medical, Inc. (FPMI) – Disease Detection at a Molecular Level
FluoroPharma Medical is focused on discovering and developing patented Positron Emission Tomography (PET) imaging products designed to improve patient management by evaluating cardiac disease at the...
View Article
